Literature DB >> 15373922

Anti-myeloperoxidase antibodies in sera from patients with propylthiouracil-induced vasculitis might recognize restricted epitopes on myeloperoxidase molecule.

H Ye1, M-H Zhao, Y Gao, X-H Guo, H-Y Wang.   

Abstract

Myeloperoxidase (MPO) is one of the major target antigens of antineutrophil cytoplasmic antibodies (ANCA) in primary systemic vasculitis. It is known that propylthiouracil (PTU) could induce MPO-ANCA-positive vasculitis. The production of anti-MPO antibodies in patients with PTU-induced vasculitis may be different from that in patients with primary microscopic polyangiitis (MPA). One possible reason for this may be differences in epitope recognition. The aim of this study is to compare the epitopes of antibodies to MPO in sera from patients with PTU-induced vasculitis (n = 10) and MPA (n = 10). The sera were collected and used to inhibit monoclonal antibodies against human MPO (3D8 and 6B9) and affinity purified, horseradish peroxidase conjugated human anti-MPO antibodies (Pab1-HRP, Pab2-HRP) in a competitive inhibition enzyme-linked immunosorbent assay (ELISA) system using soluble human MPO as solid phase ligand. The Pab1-HRP and Pab2-HRP were affinity purified from plasma exchanges of a patient with PTU-induced vasculitis and a patient with MPA, respectively. The inhibition rates were evaluated and compared between the PTU and primary MPA groups. In the PTU group all 10 sera could inhibit 3D8: the average inhibition rate was 44.7% +/- 5.0%; 9/10 sera could inhibit 6B9: the average inhibition rate was 35.6% +/- 6.0%. However, in the MPA group all 10 sera could inhibit 3D8 and 6B9; the average inhibition rates were 68.4% +/- 16.1% (P < 0.01) and 62.2% +/- 17.2% (P < 0.01), respectively. Sera in both the PTU and MPA groups could inhibit Pab1-HRP and the inhibition rates were 81.4% +/- 9.4%versus 86.6% +/- 17.2% (P > 0.05). However, the average inhibition rate for Pab2-HRP in the MPA group was significantly higher than that in the PTU group (76.3% +/- 7.8%versus 58.9% +/- 15.5%, P < 0.01). We conclude that anti-MPO antibodies from patients with PTU-induced vasculitis and from patients with primary MPA could recognize more than one epitope on the native MPO molecule. Although the epitopes overlapped between the two groups, the epitopes of anti-MPO antibodies from patients with PTU-induced vasculitis might be more restricted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15373922      PMCID: PMC1809185          DOI: 10.1111/j.1365-2249.2004.02557.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Clinical features and outcomes in children with antineutrophil cytoplasmic autoantibody-positive glomerulonephritis associated with propylthiouracil treatment.

Authors:  Mikiya Fujieda; Motoshi Hattori; Hideaki Kurayama; Yasushi Koitabashi
Journal:  J Am Soc Nephrol       Date:  2002-02       Impact factor: 10.121

2.  A comprehensive method to purify three major ANCA antigens: proteinase 3, myeloperoxidase and bactericidal/permeability-increasing protein from human neutrophil granule acid extract.

Authors:  M H Zhao; C M Lockwood
Journal:  J Immunol Methods       Date:  1996-10-16       Impact factor: 2.303

3.  Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils.

Authors:  X Jiang; G Khursigara; R L Rubin
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

4.  Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.

Authors:  R J Falk; R S Terrell; L A Charles; J C Jennette
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

5.  ANCA and predicting relapse in systemic vasculitis.

Authors:  D R Jayne; G Gaskin; C D Pusey; C M Lockwood
Journal:  QJM       Date:  1995-02

6.  Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy.

Authors:  K M Dolman; R O Gans; T J Vervaat; G Zevenbergen; D Maingay; R E Nikkels; A J Donker; A E von dem Borne; R Goldschmeding
Journal:  Lancet       Date:  1993-09-11       Impact factor: 79.321

7.  The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with hyperthyroidism.

Authors:  Ying Gao; Ming-hui Zhao; Xiao-hui Guo; Gang Xin; Yan Gao; Hai-yan Wang
Journal:  Endocr Res       Date:  2004-05       Impact factor: 1.720

8.  Anti-myeloperoxidase autoantibodies react with native but not denatured myeloperoxidase.

Authors:  R J Falk; M Becker; R Terrell; J C Jennette
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

9.  Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis.

Authors:  Y Arimura; S Minoshima; Y Kamiya; U Tanaka; K Nakabayashi; K Kitamoto; T Nagasawa; T Sasaki; K Suzuki
Journal:  Clin Nephrol       Date:  1993-11       Impact factor: 0.975

10.  Persistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow-up of 53 patients.

Authors:  P Cohen; L Guillevin; L Baril; F Lhote; L H Noel; P Lesavre
Journal:  Clin Exp Rheumatol       Date:  1995 Mar-Apr       Impact factor: 4.473

View more
  7 in total

Review 1.  Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Min Chen; Ying Gao; Xiao-Hui Guo; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2012-06-05       Impact factor: 28.314

2.  Titre and affinity of propylthiouracil-induced anti-myeloperoxidase antibodies are closely associated with the development of clinical vasculitis.

Authors:  Hua Ye; Ying Gao; Xiao-Hui Guo; Ming-Hui Zhao
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

3.  Anti-endothelial cell antibodies (AECA) in patients with propylthiouracil (PTU)-induced ANCA positive vasculitis are associated with disease activity.

Authors:  F Yu; M-H Zhao; Y-K Zhang; Y Zhang; H-Y Wang
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

4.  Epitope specificity of myeloperoxidase antibodies: identification of candidate human immunodominant epitopes.

Authors:  B F Bruner; E S Vista; D M Wynn; J A James
Journal:  Clin Exp Immunol       Date:  2011-03-14       Impact factor: 4.330

5.  Epitope analysis of anti-myeloperoxidase antibodies in propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Chen Wang; Shen-ju Gou; Peng-cheng Xu; Ming-hui Zhao; Min Chen
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

Review 6.  Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Cheng-Hua Weng; Zhi-Chun Liu
Journal:  Chin Med J (Engl)       Date:  2019-12-05       Impact factor: 2.628

7.  Epitope analysis of anti-myeloperoxidase antibodies in patients with ANCA-associated vasculitis.

Authors:  Shen-Ju Gou; Peng-Cheng Xu; Min Chen; Ming-Hui Zhao
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.